H19 (gene)
H19 | ||||||
---|---|---|---|---|---|---|
Identifiers | ||||||
Ensembl |
| |||||
UniProt |
| |||||
RefSeq (mRNA) |
|
| ||||
RefSeq (protein) |
|
| ||||
Location (UCSC) | Chr 11: 2 – 2 Mb | n/a | ||||
PubMed search | [2] | n/a |
View/Edit Human |
H19 is a
The H19 gene is expressed exclusively on one parental allele in a phenomenon known as
Gene characterization
The H19 gene contains 3
In cell lines derived from human choriocarcinomas, Kopf et al. found that transcription of H19 was under the simultaneous control of both a 5’ upstream and a 3’ downstream region.[11] Kopf et al. have suggested that this simultaneous and bidirectional regulation of H19 may involve a member of the AP2 transcription factor family.[11]
H19 gene transcription has also been shown to be activated by the presence of the E2F1 transcription factor.[12][13]
RNA product
The H19 gene codes for a 2.3 kb RNA product.[14] It is transcribed by RNA polymerase II,
After many studies, researchers finally concluded that the end product of the H19 gene is a RNA strand for the following reasons:
- The H19 RNA product is evolutionarily conserved at the nucleotide level in humans and rodents[16]
- There is no known open reading frame; the H19 mRNA contains stop codons in all 3 reading frames [15]
- The cDNA version of the human H19 does not contain the short introns that are characteristic of imprinted genes [16]
- Although the RNA sequence was highly conserved evolutionarily, at the amino acid level, there was a complete absence of conservation [16]
- Free energy (thermodynamics) analysis of the H19 RNA sequence revealed a multitude of possible secondary RNA structures, including 16 helices and various hairpin loops [16]
- In situ hybridization of the H19 RNA revealed that it localizes in a cytoplasmic ribonucleoprotein particle, leading some to suggest that the H19 RNA functions as a riboregulator.[17]
Loss of function and overexpression experiments on H19 have revealed two things:
Mice with a loss of H19 function express an overgrowth phenotype similar to babies with
- The overexpression of H19 in tissues where it is normally expressed (e.g., liver and gut) caused its lethal effects[14]
- This implies that H19 gene dosage is under strict control in the fetus
- The expression of H19 in tissues where it is normally not expressed (e.g., brain) caused its lethal effects[14]
Expression timeline
In the early placentae (6–8 weeks gestation), both parental H19 alleles (maternal and paternal) are expressed.[19][20]
After 10 weeks gestation and in full term placentae, there is exclusive expression of H19 from the maternal chromosome.[19][20] In the embryo, maternal expression of H19 is present in endodermal and mesodermal tissues.[14] The regulated expression of H19, from biallelic to monoallelic, throughout embryonic development suggests that regulation is essential for the growth of embryonic and extraembryonic tissues.[19] Immediately after birth, H19 expression is downregulated in all tissues except for skeletal muscle.[14]
Studies by Tanos et al. suggest that the accumulation of H19 RNA in skeletal muscle cells is solely due to the stabilization of that RNA in the muscle cells during differentiation.[21]
In females, H19 is expressed postnatally during puberty and pregnancy in the mammary glands, and in the uterus during pregnancy.[22]
A study by Shoshani et al. suggests that H19 is continued to be expressed in high amounts in the liver after birth, specifically in diploid hepatocytes.[23]
Epigenetics
Genomic imprinting is surmised to have arisen due to the conflicting interests of maternal and paternal genes within a pregnancy.[24]
Within a pregnancy, the father wants the mother to devote as much of her resources as possible towards the growth (benefit) of his offspring.[24] However, within the same pregnancy, the mother wants to conserve as much of her resources as possible towards future births without compromising the health of the child(ren) she is currently carrying.[24]
H19 contains a differentially methylated region that is also an imprinting control region. This imprinting control region is differentially methylated at its CpGs according to parental inheritance. Usually, the paternal copy of H19 is methylated and silent while the maternal copy is hypomethylated or unmethylated and expressed in the offspring cell. Methylation of the H19 promoter is negatively correlated with H19 expression.[25]
As methylation of the promoter reaches 100%, H19 expression from that promoter approaches 0.[25] At the same time as H19 expression decreases, the expression of IGF2, a neighboring gene on chromosome 11, increases.[25]
Cells treated with Azad, a demethylating agent, grow much slower than cells cultured in the absence of Azad.[25] At the same time, H19 expression increases while IGF2 expression decreases in the presence of Azad.[25] The reduction of IGF2 expression could be a reason for the slower growth of cells treated with Azad. As well, in a mouse bladder carcinoma cell line, where transfection of a human H19 DNA construct results in high expression of H19, the methylation of the H19 promoter reduces H19 expression.[20] The paternal H19 allele, which is silent postnatally, shows increasing methylation of CpGs in its promoter with gestation time in the fetus.[20] It appears conclusive that the H19 gene is epigenetically controlled via methylation, where methylation on or near the vicinity of one allele prevents the expression of that allele. As well, based on the results from Banet et al., it appears that functional H19 imprinting occurs during early placenta development.[20]
In addition, methylation loss at H19 imprinted gene has been observed associated with MTHFR gene promoter hypermethylation in semen samples from infertile males.[9] Similarly, the CTCF-binding site 6 region of H19 can also be hypomethylated with MTHFR gene promoter hypermethylation.[9]
Replication
A common characteristic of imprinted genes is asynchronous replication during the DNA synthesis phase of the mitotic cycle.[16] The replication of two alleles of the same gene can differ according to which parent the allele originated from.[16] On the human chromosome 11p15, the methylated paternal H19 allele replicates early in the S phase while the hypomethylated maternal allele replicates later.[16] Studies by Bergstrom et al. have determined that the later-replicating maternal H19 allele is CTCF-bound, and that it is this CTCF binding that determines the time of H19 replication.[16]
As an oncogene
Evidence for the identification of H19 as an oncogene:
- Overexpression of H19 appears to be important in the development of esophageal and colorectal cancer cells[26]
- Cells expressing H19 are able to form bigger colonies in soft agar in anchorage-independent growth assays as compared to the control.[27]
- Downregulation of H19 in breast and lung cancer cells decreases their clonogenicity and anchorage-dependent growth[28]
- Subcutaneous injection of H19 into mice promoted tumor progression[27]
- Tumors formed by injection of bladder carcinoma cells into mice express H19; prior to the injection, these bladder carcinoma cells did not express H19.[29]
- Ectopic H19 expression in vivo enhances the tumorigenic potential of carcinoma cells[30]
- c-Myc, an oncogene that functions as a regulator of gene transcription, induces H19 expression[28]
- Knocking down H19 in hypoxic stress diminishes p57 induction[30]
Evidence against the identification of H19 as an oncogene:
- The amount of H19 RNA transfected into breast cancer cells did not affect: cell proliferation, cell cycle timing or anchorage-dependent growth[27]
- Tumorigenic mesenchymal stem cells express high levels of H19 compared with non-tumorigenic mesenchymal stem cells. Knock-down of H19 in the tumorigenic cells reduced their tumor forming capacity significantly[23]
As an oncofetal RNA gene
Definition of an oncofetal gene:
- A gene expressed in tumors arising from tissues that express this gene in fetal life[31]
H19, while possessing oncogenic properties, is best defined as an oncofetal RNA gene because:
- The final product of the H19 gene is RNA[31]
- H19 is highly expressed prenatally and downregulated postnatally[19]
- Postnatally, H19 is expressed at high levels in cancer cells[14]
Role in cancer
Increased H19 expression is found in the following cancers: adrenocortical neoplasms, choriocarcinomas, hepatocellular carcinomas, bladder cancers, ovarian serous epithelial cancers, head and neck carcinomas, endometrial cancer, breast cancer, acute T cell leukemia/lymphoma, Wilms' tumor, testicular germ cell cancer, esophageal cancer and lung cancer.[12][19][20][21][25][32][33][34][35]
Genome instability
Cellular DNA integrity is often compromised in cancer. Genome instability can refer to the accumulation of extra copies of DNA/chromosomes, chromosomal translocations, chromosomal inversion, chromosome deletions, single stranded breaks in DNA, double stranded breaks in DNA, the intercalation of foreign substances into the DNA double helix, or any abnormal changes in DNA tertiary structure that can cause either the loss of DNA, or the misexpression of genes. It appears that H19 expression is tightly linked to the ploidy of the cell. Diploid liver cells express high levels of H19, whereas the polyploid cell fraction do not express H19. Also, diploid mesenchymal stem cells express high levels of H19 compared to polyploid mesenchymal stem cells. Knock-down of H19 lead to increased polyploidization of mesenchymal stem cells, and induced polyploidy resulted in reduced expression of H19, providing a direct link between H19 expression and the amount of DNA within the cell.[23]
Adrenocortical neoplasms
In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible cause for the downregulation of H19, Gao et al. studied the methylation of 12 CpG sites in the H19 promoter in normal, hyperplasia, adenoma and carcinoma adrenals. They found that in carcinomas, there was more methylation of CpGs than in normal, hyperplasia and adenoma adrenals.[25] Consequently, normal H19 expression was detectable in normal and hyperplasia adrenals, but in carcinomas and surprisingly, adenomas, there was a lower H19 expression that was coupled with detectable (increased) IGF2 expression.[25]
The presence of IGF2 RNA expression when H19 RNA was downregulated provides further evidence that IGF2 expression is tightly coupled to and dependent on the absence of H19 expression. As well, the loss of H19 in adrenal cancers may be indicative of tumor suppressor activity by H19, leading Gao et al. to suggest that the loss of H19 and subsequent gain of IGF2 may be involved in adrenal
The mean percent methylation of H19 CpGs at sites 13 and 14, after the transcription start site, is insignificant between normal, hyperplasia, adenoma and carcinoma adrenals. This is because methylation of CpGs after the transcription start site is assumed to interfere with RNA polymerase II during transcription. Another point of interest is the significant difference in CpG methylation at site 11 between normal and hyperplasia adrenals. The mean percent CpG methylation at site 11 for hyperplasia and adenoma adrenals is significantly different from that of normal adrenals and carcinoma adrenals, leading Gao et al. to suggest that site 11 is the initial methylated CpG that eventually leads to widespread methylation of the H19 promoter.[25]
Choriocarcinomas
Choriocarcinomas, in contrast to adrenal carcinomas, have upregulated H19 and downregulated IGF2 expression.[19] The upregulated H19 expression, however, came from alleles that were fully methylated.[19] Surgically removed choriocarcinomas from human patients also exhibited a heavily methylated H19 promoter with enhanced H19 expression.[19] This led researchers Arima et al. to suggest that in cases of choriocarcinomas, the H19 promoter was mutated, allowing it to overcome the transcriptional repression of promoter CpG methylation.
Hepatocellular carcinoma
In hepatocellular carcinoma, the expression of H19 and IGF2 usually changes from monoallelic to biallelic.[30] In in vitro studies, culturing hepatocellular carcinoma cell lines in hypoxic condition upregulated H19 expression.[30] Whether or not the loss of imprinting for the H19 promoter is a characteristic of hepatocellular carcinoma is not known, as some cell lines exhibit loss of imprinting while others did not.
Bladder cancers
Bladder mucosa is one of the tissues that express high levels of H19 RNA prenatally.[35] In bladder cancers, H19 is also upregulated and present in most stages.[20] The presence of H19 RNA was strongest in bladder carcinomas (sampled in situ) that tend to progress rapidly to invasive cancer as well as invasive transitional cell carcinomas.[36]
In samples of bladder carcinoma, loss of imprinting at the H19 loci were observed.[29] Verhaugh et al. investigated various polymorphisms in the H19 gene and found that some heterozygous SNP polymorphisms, such as rs2839698 TC, were associated with a decreased risk of developing non-muscle invasive bladder cancer as well as bladder cancer overall; however, this association disappeared for homozygotes (CC).[37]
Endometrial/ovarian cancer
In normal endometrial tissue, there is no H19 expression; however, in endometrial cancer, H19 is expressed.[21] The expression level of H19 RNA in the epithelial cells of the endometrium increases as tissue differentiation is lost in endometrial cancer.[21]
In ovarian cancers, 75% of low malignancy tumors and 65% of invasive ovarian carcinomas are H19 RNA positive.[32]
Breast cancer
Normal breast tissue does not express H19 RNA, except during puberty and pregnancy in the mammary glands.[38]
However, in
In experiments conducted by Doyle et al., it was found that MCF-7, a breast adenomacarcinoma cell line,[39] did not express the H19 gene; however a subline of MCF-7 with a multidrug resistance phenotype, MCF-7/AdrVp, had upregulation of H19.[34] Curiously,
NCI-H1688, a human lung carcinoma cell line that displays multidrug resistance, also overexpress p95 (NCA-90) and H19.[34] No other cell lines with the multidrug resistance phenotype have been found to overexpress p95 (NCA-90) in conjunction with H19.[34]
Larynx cancer
H19 is overexpressed in laryngeal squamous cell carcinomas that relapse as compared to those that do not relapse. In a pilot study aimed at the development of a prognostic classifier for this cancer H19 was the strongest predictor of relapse. It was overexpressed in cancers that later developed local or distant recurrence. Its expression did not correlate with the expression of IGF2 and H19 overexpression is unlikely to be a simple consequence of loss of imprinting of the locus containing H19 and IGF2 [42]
Wilms' tumour
Participation in signaling pathways
The exact role of H19 RNA within the cell is currently not known. There are various known substances and conditions that are known to activate H19 transcription and there are various known effects of H19 RNA on cell cycle activity/status, although precisely how H19 RNA exerts these effects is still unknown.
Upstream effectors – hormonal regulation
A previous study conducted by Adriaenssens et al. on H19 correlated an overexpression of H19 with the presence of steroid receptors.[22]
Further studies found that
Downstream effects – angiogenesis, metabolism, tissue invasion and migration
When a cancer bladder cell line, T24P, which does not express H19 was transfected with a DNA construct expressing the H19 gene under the control of the cytomegalovirus promoter, many changes were seen in the resulting cells when compared to both the original T24P cell line and a H19-antisense DNA construct transfected T24P cell line. While there was no difference in proliferation in 10% FCS (normal condition) between the 3 cell lines, when grown in 0.1% FCS (starved serum), the H19-transfected cells maintained their rate of growth while both the control and the antisense H19 transfected cells decreased their rate of proliferation by approximately 50%.[44]
When p57 induction in 0.1% FCS media was measured in the 3 cell lines, both the control and antisense H19 transfected cells had significantly upregulated p57; however, the H19-transfected cells showed a significant downregulation of p57 in 0.1% FCS as compared to 10% FCS.
An examination of the differences in gene expressed between the H19 transfected cells and the antisense H19 transfected cells showed that the following genes were upregulated:
Lottin et al. also found that the overexpression of H19 positively regulates post-transcriptionally thioredoxin.[45] Thioredoxin is a protein crucial to the reduction-oxidation reactions involved in metabolism within a cell, and is often found at high levels in cancerous tissues that also overexpress H19 RNA.[45]
IGF2
H19 and IGF2 expression are closely linked, as they are expressed in the same tissues during fetal development, albeit from differing parental alleles.[18]
This coupled expression is only lost in cases of loss of imprinting (inherited CpG methylated) or promoter mutation.[46]
The hypermethylation of the H19 promoter on the paternal allele plays a vital role in allowing the expression of the paternal allele of IGF2.[25] In
It is of interest to note that mice inheriting a deleted maternal H19 and a deleted paternal IGF2 gene were indistinguishable from wildtype mice in birth weight and postnatal growth.[47] Mice inheriting only a deleted maternal H19 gene, however, displayed somatic overgrowth while mice inheriting only a deleted paternal IGF2 gene displayed somatic undergrowth when compared to wildtype mice.[47] This indicates that the loss of H19 is not lethal, H19 expression governs IGF2 repression, and the overexpression of IGF2 is responsible for the overgrowth phenotype observed in the maternal inheritance of a deleted H19 gene.[47]
Cancer therapy
While the functions of the H19 RNA in the cell are still unclear, its presence in the many types of carcinoma cells suggest that it can be used as a tumor marker for initial diagnosis, cancer recurrence and malignant potential.[21][36][48]
Gene therapy
The activation of the H19 promoter in cancerous cells (and its silence in normal tissues) has led to the suggestion of using the H19 promoter in gene therapy to drive the expression of cytotoxic genes in tumorigenic cells.[20] Gene therapy trials utilizing the H19 promoter to drive the expression of cytotoxic genes are currently being tested on mice.[20]
Drug discovery
A plasmid composed of the H19 gene regulatory sequences that drive the expression of the 'A' strand of Diphtheria Toxin (DT-A), is undergoing clinical testing as a treatment for superficial bladder cancer,[49] ovarian cancer[50] and pancreatic cancer.[51] The plasmid, designated BC-819 (or DTA-H19), embodies a targeted therapy approach, in that the plasmid enters all dividing cells, but the DT-A expression is triggered by the presence of H19 transcription factors found only in tumor cells, thus destroying the tumor without affecting normal cells.
In a double-center, dose escalation Phase I/IIa clinical trial of BC-819 as a treatment for superficial bladder cancer,[52] no severe adverse events related to the plasmid were detected, and tumor responses were observed in more than 70% of patients, including those with a still not-optimized therapeutic dose and regimen.
BC-819 was previously tested in human compassionate use for the treatment of superficial bladder cancer, ovarian cancer and metastatic liver cancer. The bladder cancer patient, who was a candidate for radical cystectomy when he was treated in 2004, reported no cancer recurrence and no side effects.[52] The ovarian cancer patient experienced a 50% decline in the amount of the ovarian cancer marker protein CA-125 in her blood as well as a significant decrease in the number of cancerous cells in her ascitic fluid. The patient suffering from metastatic liver cancer was treated with direct injection of BC-819 into the tumor, with considerable tumor necrosis observed.
Pharmacogenomics
While the expression profile of H19 in most cancer types is known, the role of H19 RNA in influencing cancer cell response to drug treatment is still unknown. However, recent studies have discovered the expression of thioredoxin and p95 (NCA-90) in cancer cells when H19 RNA is present in high quantities.[34][45] This knowledge can lead to a more personalized cancer treatment plan; for example, the expression of p95 in a H19-overexpressing cancer cell may indicate higher tolerance of drug toxicity, so cancer treatment for an individual with high levels of H19 (and p95) may focus more on radiotherapy or immunotherapy instead of chemotherapy.
Immunotherapy
It is not currently known if H19 expression can be used to induce an anti-cancer response in immune cells.
References
- ^ a b c ENSG00000288237 GRCh38: Ensembl release 89: ENSG00000130600, ENSG00000288237 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- PMID 19762426.
- ^ "H19: imprinted maternally expressed transcript (non-protein coding) (Homo sapiens)". Entrez Gene. National Center for Biotechnology Information. Retrieved 2008-06-06.
- S2CID 35338859.
- S2CID 22194553.
- PMID 1953776.
- ^ Online Mendelian Inheritance in Man (OMIM): H19 Gene - 103280
- ^ PMID 23975186.
- ^ S2CID 34185893.
- ^ S2CID 30015086.
- ^ S2CID 46427539.
- ^ PMID 15985428.
- ^ PMID 2044956.
- ^ PMID 1688465.
- ^ PMID 17329968.
- ^ Szymanski M, Erdmann VA, Barciszewski J. "Eurekah - Riboregulators: An Overview". Bioscience Chapter Database. Landes Bioscience. Archived from the original on 2007-07-06. Retrieved 2008-06-06.
- ^ PMID 7544754.
- ^ PMID 9062579.
- ^ S2CID 8842695.
- ^ S2CID 43533877.
- ^ PMID 10442637.
- ^ PMID 23047867.
- ^ PMID 2035190.
- ^ PMID 11889182.
- PMID 8564957.
- ^ PMID 12419837.
- ^ PMID 16707459.
- ^ S2CID 21179965.
- ^ PMID 17786216.
- ^ PMID 9208812.
- ^ PMID 10428315.
- S2CID 8775403.
- ^ PMID 8674037.
- ^ PMID 10751088.
- ^ PMID 7855987.
- PMID 18262338.
- ^ PMID 9811352. Archived from the originalon 2003-09-12.
- ^ "Breast Cell Line MCF-7". Cancer Biology - Breast Cancer Cell Line Database. University of Texas M. D. Anderson Cancer Center. Retrieved 2008-06-06.
- PMID 9407950.
- PMID 9219849.
- PMID 21481529.
- ^ Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ, Tugnait S, Thevanesan C, Young MD, Oliver TRW, Oostveen M, Collord G, Tarpey PS, Cagan A, Hooks Y, Brougham M, Reynolds BC, Barone G, Anderson J, Jorgensen M, Burke GAA, Visser J, Nicholson JC, Smeulders N, Mushtaq I, Stewart GD, Campbell PJ, Wedge DC, Martincorena I, Rampling D, Hook L, Warren AY, Coleman N, Chowdhury T, Sebire N, Drost J, Saeb-Parsy K, Stratton MR, Straathof K, Pritchard-Jones K, Behjati S (2019) Embryonal precursors of Wilms tumor. Science 366(6470):1247-1251
- ^ S2CID 38724288.
- ^ S2CID 29493356.
- PMID 9570364.
- ^ S2CID 2998931.
- PMID 11193051.
- ^ "Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer". ClinicalTrials.gov. U.S. National Institutes of Health. 2009-08-31. Retrieved 2010-01-14.
- ^ "Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer With Symptomatic Ascites". ClinicalTrials.gov. U.S. National Institutes of Health. 2009-12-03. Retrieved 2010-01-14.
- ^ "Phase 1/2a DTA-H19 in Patients With Unresentable Pancreatic Cancer". ClinicalTrials.gov. U.S. National Institutes of Health. 2009-11-09. Retrieved 2010-01-14.
- ^ PMID 18950807.
External links
Online Mendelian Inheritance in Man (OMIM): H19 Gene - 103280